Vir CEO George Scangos (L) and chief corporate affairs officer Bolyn Hubby

In post-Covid life, Vir looks to stomp out in­fluen­za in up to $1B BAR­DA con­tract that boosts GSK-al­lied mAb

With its Covid-19 mon­o­clon­al an­ti­body side­lined in the US since April and plans for full ap­proval no longer in the cards, Vir Biotech­nol­o­gy is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.